$DJIA$NASDAQ$MESO announced today that Remestemcel-L has been effectively used against COVID-19 in China. Mesoblast has already concluded phase 3 trials and filed a BLA with the FDA in January for treatment of GVHD in children, approval which is anticipated 1H 2020.
Separate approval would be needed for COVID-19 but all the heavy lifting is final. investorsmedia.mesoblast.co...smh.com.au/business/compan
Emergency Use Authorization (EUA), page-33
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.005(0.39%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $1.653M | 1.285M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16781 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 9777 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |